SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-036508
Filing Date
2021-02-10
Accepted
2021-02-10 17:29:07
Documents
13
Period of Report
2021-02-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d131053d8k.htm   iXBRL 8-K 44302
5 GRAPHIC g131053img01.jpg GRAPHIC 52720
  Complete submission text file 0001193125-21-036508.txt   290099

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tvtx-20210210.xsd EX-101.SCH 3093
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvtx-20210210_lab.xml EX-101.LAB 17373
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvtx-20210210_pre.xml EX-101.PRE 10968
6 EXTRACTED XBRL INSTANCE DOCUMENT d131053d8k_htm.xml XML 3304
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 21615239
SIC: 2834 Pharmaceutical Preparations